{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:18:33Z","timestamp":1790957913809,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen"},{"name":"Dermavant"},{"name":"DS Biopharma"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Glenmark"},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Asana Biosciences"},{"name":"Innovaderm"},{"DOI":"10.13039\/100013988","name":"Dermira","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013988","id-type":"DOI","asserted-by":"publisher"}]},{"name":"LEO Pharma"},{"name":"Novan"},{"DOI":"10.13039\/501100004095","name":"Kyowa Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Concert"},{"name":"Union Therapeutics"},{"name":"Ralexar"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jaci.2019.06.047","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T19:18:59Z","timestamp":1565723939000},"page":"1274-1289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"title":["Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial"],"prefix":"10.1016","volume":"144","author":[{"given":"Robert","family":"Bissonnette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B.","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisleen","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanbo","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Vranic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek S.","family":"Purohit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Vlahos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeriel D.","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Saint-Cyr Proulx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Ports","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-324X","authenticated-orcid":false,"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl","key":"10.1016\/j.jaci.2019.06.047_bib1","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.anai.2017.09.055","article-title":"Immunologic, microbial, and epithelial interactions in atopic dermatitis","volume":"120","author":"Brunner","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib3","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.jaci.2017.04.004","article-title":"Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march","volume":"139","author":"Czarnowicki","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/pai.12095","article-title":"Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization","volume":"24","author":"Silverberg","year":"2013","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/DER.0000000000000034","article-title":"Associations of childhood eczema severity: a US population-based study","volume":"25","author":"Silverberg","year":"2014","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaci.2019.06.047_bib6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.det.2017.02.002","article-title":"Public health burden and epidemiology of atopic dermatitis","volume":"35","author":"Silverberg","year":"2017","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaci.2019.06.047_bib7","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jaci.2015.08.013","article-title":"Petrolatum: barrier repair and antimicrobial responses underlying this \u201cinert\u201d moisturizer","volume":"137","author":"Czarnowicki","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","article-title":"Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape","volume":"120","author":"Boguniewicz","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jaci.2015.12.1323","article-title":"A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis","volume":"138","author":"Brunner","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib10","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2017.01.027","article-title":"Molecular signatures order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitis","volume":"140","author":"Guttman-Yassky","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaci.2014.10.037","article-title":"Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection","volume":"135","author":"Esaki","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/exd.13336","article-title":"Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment","volume":"27","author":"Guttman-Yassky","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib13","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jaci.2014.11.015","article-title":"The translational revolution and use of biologics in patients with inflammatory skin diseases","volume":"135","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib14","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaci.2015.03.003","article-title":"RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications","volume":"135","author":"Suarez-Farinas","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/exd.13808","article-title":"The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition","volume":"28","author":"Guttman-Yassky","year":"2019","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaci.2017.07.006","article-title":"Therapeutic pipeline for atopic dermatitis: end of the drought?","volume":"140","author":"Paller","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl","key":"10.1016\/j.jaci.2019.06.047_bib17","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jaad.2017.11.056","article-title":"Phosphodiesterase 4 inhibitors","volume":"78","author":"Zebda","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib18","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/00015555924447","article-title":"Diagnostic features of atopic dermatitis","volume":"60","author":"Hanifin","year":"1980","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2019.06.047_bib20","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/bjd.13235","article-title":"Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12-17 years of age","volume":"171","author":"Gooderham","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/00015550310003791","article-title":"An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion","volume":"83","author":"Mrowietz","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2019.06.047_bib22","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.jaci.2014.03.003","article-title":"Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology","volume":"133","author":"Khattri","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaci.2011.05.042","article-title":"Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response","volume":"128","author":"Tintle","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib25","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2340\/00015555-1246","article-title":"Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus","volume":"92","author":"Phan","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2019.06.047_bib26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Thaci","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2019.06.047_bib27","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaad.2016.04.054","article-title":"Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)","volume":"75","author":"Simpson","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib28","series-title":"Non invasive diagnostic techniques in clin dermatology","first-page":"345","article-title":"Closed-chamber methods: AquaFlux and VapoMeter","author":"Imhof","year":"2014"},{"key":"10.1016\/j.jaci.2019.06.047_bib29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaci.2018.07.028","article-title":"Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab","volume":"143","author":"Brunner","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib30","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib31","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","article-title":"Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing","volume":"136","author":"Suarez-Farinas","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib32","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.anai.2018.08.024","article-title":"Atopic dermatitis in African American patients is TH2\/TH22-skewed with TH1\/TH17 attenuation","volume":"122","author":"Sanyal","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib34","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jaci.2010.12.1124","article-title":"Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities","volume":"127","author":"Suarez-Farinas","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"Hanzelmann","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jaci.2019.06.047_bib36","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jaad.2017.06.010","article-title":"Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis","volume":"77","author":"Eichenfield","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib37","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12920-015-0133-x","article-title":"Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways","volume":"8","author":"Ewald","year":"2015","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.jaci.2019.06.047_bib39","doi-asserted-by":"crossref","first-page":"15178","DOI":"10.1073\/pnas.1416714111","article-title":"Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells","volume":"111","author":"Luo","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2019.06.047_bib40","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ajhg.2014.12.004","article-title":"Genome-wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms","volume":"96","author":"Baurecht","year":"2015","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaci.2019.06.047_bib41","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jaci.2014.03.009","article-title":"Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response","volume":"134","author":"Dhingra","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib42","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib43","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/hmg\/ddq019","article-title":"A milieu of regulatory elements in the epidermal differentiation complex syntenic block: implications for atopic dermatitis and psoriasis","volume":"19","author":"de Guzman Strong","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jaci.2019.06.047_bib44","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2133.2007.07999.x","article-title":"On the role of the epidermal differentiation complex in ichthyosis vulgaris, atopic dermatitis and psoriasis","volume":"157","author":"Hoffjan","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib45","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/1346-8138.12321","article-title":"Genome-wide association studies of atopic dermatitis","volume":"41","author":"Tamari","year":"2014","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib46","article-title":"Cyclic adenosine monophosphate signaling in inflammatory skin disease","volume":"07","author":"Levy","year":"2016","journal-title":"J Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib47","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.2174\/0929867324666170530093902","article-title":"Phosphodiesterase 4 inhibitors in immune-mediated diseases: mode of action, clinical applications, current and future perspectives","volume":"24","author":"Sakkas","year":"2017","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jaci.2019.06.047_bib48","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","article-title":"Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in\u00a0vitro and in a model of psoriasis","volume":"159","author":"Schafer","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaci.2019.06.047_bib49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fimmu.2016.00123","article-title":"The cAMP pathway as therapeutic target in autoimmune and inflammatory diseases","volume":"7","author":"Raker","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib50","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaci.2019.06.047_bib51","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jaci.2019.06.047_bib52","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/exd.13112","article-title":"Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"26","author":"Khattri","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib53","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jaad.2005.12.028","article-title":"Corticosteroid classes: a quick reference guide including patch test substances and cross-reactivity","volume":"54","author":"Jacob","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib54","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3390\/jcm4050858","article-title":"Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics","volume":"4","author":"Mansouri","year":"2015","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaci.2019.06.047_bib55","first-page":"1477","article-title":"Biologic therapy for atopic dermatitis: moving beyond the practice parameter and guidelines","volume":"5","author":"Boguniewicz","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib56","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1016\/j.jaci.2018.02.040","article-title":"Early-onset pediatric atopic dermatitis is characterized by TH2\/TH17\/TH22-centered inflammation and lipid alterations","volume":"141","author":"Brunner","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib57","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib58","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/intimm\/dxy015","article-title":"Multipolarity of cytokine axes in the pathogenesis of atopic dermatitis in terms of age, race, species, disease stage and biomarkers","volume":"30","author":"Nomura","year":"2018","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib59","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jaci.2018.02.047","article-title":"Serum from Asian patients with atopic dermatitis is characterized by TH2\/TH22 activation, which is highly correlated with nonlesional skin measures","volume":"142","author":"Wen","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib60","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jaci.2014.04.021","article-title":"Filaggrin-stratified transcriptomic analysis of pediatric skin identifies mechanistic pathways in patients with atopic dermatitis","volume":"134","author":"Cole","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib61","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaci.2015.05.049","article-title":"Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2\/TH1 cell imbalance, whereas adults acquire CLA(+) TH22\/TC22 cell subsets","volume":"136","author":"Czarnowicki","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib62","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaci.2016.09.060","article-title":"Alterations in B-cell subsets in pediatric patients with early atopic dermatitis","volume":"140","author":"Czarnowicki","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib63","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jaci.2016.07.013","article-title":"Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin","volume":"138","author":"Esaki","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib64","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","article-title":"Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?","volume":"48","author":"Guttman-Yassky","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib65","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/exd.13514","article-title":"Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment","volume":"27","author":"Kaufman","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib66","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1398-9995.2010.02540.x","article-title":"Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity","volume":"66","author":"Kezic","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.06.047_bib67","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s41232-017-0044-7","article-title":"The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus","volume":"37","author":"Rerknimitr","year":"2017","journal-title":"Inflamm Regen"},{"key":"10.1016\/j.jaci.2019.06.047_bib68","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaci.2013.04.046","article-title":"Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis","volume":"132","author":"Suarez-Farinas","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaci.2019.06.047_bib70","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaci.2011.01.053","article-title":"Contrasting pathogenesis of atopic dermatitis and psoriasis\u2014part I: clinical and pathologic concepts","volume":"127","author":"Guttman-Yassky","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib71","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/itx.0000000000000012","article-title":"Effect of crisaborole topical ointment, 2%, on atopic dermatitis\u2013associated pruritus: an extended analysis of 2 phase 3 clinical trials","volume":"3","author":"Yosipovitch","year":"2018","journal-title":"Itch"},{"key":"10.1016\/j.jaci.2019.06.047_bib72","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40257-016-0204-6","article-title":"Tolerability of crisaborole ointment for application on sensitive skin areas: a randomized, double-blind, vehicle-controlled study in healthy volunteers","volume":"17","author":"Zane","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib73","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/pde.12872","article-title":"Crisaborole topical ointment, 2% in patients 2 to 17 years of age with atopic dermatitis: a phase 1b, open-label, maximal-use systemic exposure (MUSE) study","volume":"33","author":"Zane","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib74","first-page":"172","article-title":"Post hoc analyses of the effect of crisaborole topical ointment, 2% on atopic dermatitis: associated pruritus from phase 1 and 2 clinical studies","volume":"15","author":"Draelos","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib75","first-page":"1394","article-title":"A phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis","volume":"14","author":"Stein Gold","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib76","first-page":"1108","article-title":"Crisaborole topical ointment, 2% in adults with atopic dermatitis: a phase 2a, vehicle-controlled, proof-of-concept study","volume":"14","author":"Murrell","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib77","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/pde.12780","article-title":"Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis: an open-label phase 2a study","volume":"33","author":"Tom","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib78","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMra074081","article-title":"Atopic dermatitis","volume":"358","author":"Bieber","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2019.06.047_bib79","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jid.2018.10.043","article-title":"A phase 2 randomized trial of apremilast in patients with atopic dermatitis","volume":"139","author":"Simpson","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib80","first-page":"835","article-title":"Mechanisms underlying the clinical effects of apremilast for psoriasis","volume":"17","author":"Pincelli","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib81","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jaad.2012.10.064","article-title":"Novel systemic drugs for psoriasis: mechanism of action for apremilast, a specific inhibitor of PDE4","volume":"68","author":"Schafer","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib82","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity","volume":"26","author":"Schafer","year":"2014","journal-title":"Cell Signal"},{"key":"10.1016\/j.jaci.2019.06.047_bib83","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1759720X10381432","article-title":"Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases","volume":"2","author":"Schett","year":"2010","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jaci.2019.06.047_bib84","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.4049\/jimmunol.178.8.4820","article-title":"Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D","volume":"178","author":"Peter","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib85","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s40265-017-0784-3","article-title":"Phosphodiesterase 4 inhibitor therapies for atopic dermatitis: progress and outlook","volume":"77","author":"Ahluwalia","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jaci.2019.06.047_bib86","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/jpet.116.232819","article-title":"Treatment of skin inflammation with benzoxaborole phosphodiesterase inhibitors: selectivity, cellular activity, and effect on cytokines associated with skin inflammation and skin architecture changes","volume":"358","author":"Dong","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaci.2019.06.047_bib87","first-page":"390","article-title":"Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis","volume":"15","author":"Jarnagin","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib88","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s13075-015-0771-6","article-title":"Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors","volume":"17","author":"Perez-Aso","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2019.06.047_bib89","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaci.2018.05.039","article-title":"Synergistic cytokine effects as apremilast response predictors in patients with psoriasis","volume":"142","author":"Garcet","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib90","doi-asserted-by":"crossref","first-page":"906349","DOI":"10.1155\/2015\/906349","article-title":"The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1)","volume":"2015","author":"Schafer","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jaci.2019.06.047_bib91","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40259-015-0144-3","article-title":"Selective phosphodiesterase inhibitors for psoriasis: focus on apremilast","volume":"29","author":"Gooderham","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.jaci.2019.06.047_bib92","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.it.2012.11.005","article-title":"The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses","volume":"34","author":"Lowes","year":"2013","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib93","doi-asserted-by":"crossref","first-page":"AB47","DOI":"10.1016\/j.jaad.2017.04.201","article-title":"Apremilast reduces IL-17F, IL-17A, IL-22, and TNF-a plasma protein levels in patients with moderate to severe plaque psoriasis: pharmacodynamic and correlative results from phase 2\/3 studies [abstract]","volume":"76","author":"Krueger","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.06.047_bib94","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","article-title":"GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis","volume":"144","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.047_bib95","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/09546634.2017.1350256","article-title":"High rates of secondary non-adherence causes decreased efficacy of 0.1% topical tacrolimus in adult eczema patients: results from a multicenter clinical trial","volume":"29","author":"Yang","year":"2018","journal-title":"J Dermatol Treat"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167491931036X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167491931036X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:20:25Z","timestamp":1758792025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009167491931036X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":95,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S009167491931036X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2019.06.047","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2019.06.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2019 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}